MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/17562864261468464

Медицинская библиотека · Therapeutic advances in neurological disorders · 2026

Medical cannabis improved self-reported spasticity rating in patients with chronic spinal cord injury: a placebo-controlled, double-blind, crossover pilot clinical trial.

Boonthanakorn Nattha, Pattanakuhar Sintip, Kammuang-Lue Pratchayapon, Tongprasert Siam, Kovindha Apichana

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Previous studies demonstrated that cannabinoids may reduce spasticity in patients with spinal cord injury (SCI); however, the effect of naturally extracted THC:CBD oil, the most commonly used naturally extracted cannabinoids, has yet to be elucidated.

OBJECTIVES

To assess the effect of a 1:1 THC:CBD oil on reducing spasticity in chronic SCI patients.

DESIGN

A single-center, placebo-controlled, double-blind crossover clinical trial.

METHODS

Sixteen chronic SCI patients with intractable spasticity were randomly assigned to either the intervention (1:1 THC:CBD oil) or control (placebo) phase for 1 month, then crossed over. The primary outcome (combined Ashworth Scale [AS] of all involved muscle groups) and the secondary outcomes, including patient-rated visual analog scale (VAS) of spasticity, were assessed before and after both phases and analyzed using a multilevel mixed-effects model.

RESULTS

All participants completed the study. The average (SD) dose of THC:CBD oil was 11.6 (1.3) mg. No significant difference in the total AS score for all involved muscle groups was found between the pre- and post-treatment phases, or between the experimental and control phases (all p > 0.05). A significant reduction was observed in the patient rating VAS (effect size = -13.9 [95% CI: -25.5 to -2.3; p = 0.010).

CONCLUSION

In people with chronic SCI who had intractable spasticity, there was no statistically significant effect of 1:1 THC:CBD oil on spasticity-related outcomes, except for patient rating VAS reduction. Further studies are needed to evaluate the efficacy of higher doses of THC (>12 mg/day) and to use patient-reported spasticity scores as the primary outcome measure.

TRIAL REGISTRATION: The study was registered with the Thai Clinical Trials Registry (TCTR identification number: TCTR20220329001).

Для цитирования: Boonthanakorn Nattha, Pattanakuhar Sintip, Kammuang-Lue Pratchayapon, Tongprasert Siam, Kovindha Apichana. Medical cannabis improved self-reported spasticity rating in patients with chronic spinal cord injury: a placebo-controlled, double-blind, crossover pilot clinical trial.. Therapeutic advances in neurological disorders. 2026. DOI: 10.1177/17562864261468464.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.